An Open-Label, Multicenter, Dose Escalation and Expansion Phase 1B Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Activity of RO6958688 in Combination with Atezolizumab in Patients with Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

What is the purpose of this trial?

This is an open-label, multi-center, dose escalation and expansion Phase IB clinical study of RO6958688 in combination with atezolizumab.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Hoffman-La Roche

Dates: 10/07/2016 - 03/01/2018

Last Updated: 02/22/2018

Study HIC#: 1603017493